CMUS-ABS and CCMUS: High-Risk States in Clonal Hematopoiesis

September 25, 2026

New Horizons in Leukemia Research:
Selected Papers in Focus

Background

Clonal hematopoiesis (CH) refers to the expansion of blood cells derived from a single mutated hematopoietic stem cell. It is associated with an increased risk of myeloid neoplasms (MNs) as well as cardiovascular and kidney disease.

Chronic myelomonocytic leukemia (CMML) is an overt myeloid neoplasm within this spectrum. Its core diagnostic criteria include peripheral blood monocytosis of at least 0.5 x 109 monocytes/L and monocytes accounting for at least 10% of leukocytes, blasts comprising less than 20% of cells in peripheral blood and bone marrow, as well as evidence of clonality (Arber et al., 2022).

The International Consensus Classification (ICC) additionally introduced the categories clonal monocytosis of undetermined significance (CMUS) and clonal cytopenia and monocytosis of undetermined significance (CCMUS). These entities describe clonal hematopoietic alterations with concurrent monocytosis that do not meet the diagnostic criteria for CMML. CCMUS is characterized by the additional presence of cytopenia.

Using clinical, genomic, and longitudinal data from 431,531 UK Biobank participants, Dunn et al. investigated the prevalence and clinical relevance of CMUS and CCMUS. The researchers distinguished CMUS with absolute monocytosis—at least 1.0 x 109  monocytes/L and at least 10% of leukocytes (CMUS-ABS)—from CMUS with relative monocytosis—at least 10% of leukocytes but an absolute monocyte count of at least 0.5 x 109 and less than 1.0 x 109  monocytes/L (CMUS-REL). CCMUS was assigned when cytopenia was also present.

Study Results in Detail

Prevalence and clinical relevance: CMUS and CCMUS were uncommon among UK Biobank participants, with a combined prevalence of 0.4%. CMUS-ABS and CCMUS had a mutation profile distinct from CMUS-REL: TET2 and spliceosome-factor mutations, particularly SRSF2, were more frequent in CMUS-ABS and CCMUS. In contrast, DNMT3A mutations predominated in CMUS-REL, resembling the pattern seen in clonal hematopoiesis without monocytosis.

Increased disease risk: CMUS-ABS and CCMUS were associated with a high risk of myeloid neoplasms. The 10-year incidence was 9.1% for CMUS-ABS and 18.5% for CCMUS, compared with 5.3% for clonal cytopenia of undetermined significance (CCUS) without monocytosis. Myeloproliferative neoplasms (MPNs) were the most frequent progression outcome in CMUS-ABS, whereas myelodysplastic neoplasms (MDS) occurred most frequently in CCMUS. Progression to CMML was also observed. CMUS-ABS and CCMUS were also associated with an increased risk of cardiovascular disease as well as acute and chronic kidney disease.

More precise definitions: Men had higher relative and absolute monocyte counts; 70.6% of all CMUS/CCMUS cases were male. Dunn et al. therefore proposed sex-specific monocyte thresholds with higher thresholds for men: at least 0.6 x 109 monocytes/L and at least 11.5% of leukocytes. Cases with an isolated DNMT3A mutation had an indolent course and a low risk of progression. Excluding isolated DNMT3A mutations and introducing sex-specific monocyte thresholds improved risk stratification.

MoSAIC for identifying SRSF2-mutated monocytosis: SRSF2 mutations were associated with elevated monocyte counts and a high risk of myeloid neoplasms. Dunn et al. therefore developed MoSAIC (Monocytosis with SRSF2 Automatically Inferred from Counts), a machine-learning classifier that estimates the likelihood of an SRSF2 mutation in individuals with monocytosis using routine complete blood count parameters. Independent prospective validation is required before clinical implementation. 

Visual abstract of the study by Dunn et al. on CMUS and CCMUS, showing the study design and key findings on disease risks, mutation profiles, sex-specific monocyte thresholds, and MoSAIC.
Visual abstract on the prevalence and clinical relevance of CMUS and CCMUS: the study underscores both entities as distinct high-risk states within the spectrum of clonal hematopoiesis. © Dunn et al., Blood, 2026.

Conclusion

The findings of Dunn et al. indicate that CMUS and CCMUS are clinically relevant entities within the spectrum of clonal hematopoiesis and are frequently associated with an increased risk of myeloid neoplasms. The authors recommend refining the definitions through sex-specific monocyte thresholds and exclusion of isolated DNMT3A mutations to enable more accurate risk stratification. 

References

Dunn WG et al. The prevalence and clinical significance of clonal monocytosis. Blood 2026;147(25):3039–3050.

Arber DA et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140(11):1200–1228.

The author

»Do you have questions about CMUS and CCMUS, or would you like further information about the study? Please feel free to E-Mail me.«

Dr. rer. nat. Katharina Hörst

You might also be interested in

Dr. rer. nat. Sabine Riedel
at 26.04.2027

MLL MVZ Academy 2027

The next MLL MVZ Academy will take place from April 26 to 28, 2027. The three-day workshop combines theory, practice, and discussions on modern leukemia and lymphoma diagnostics. Register by March 1, 2027!

Read more

Dr. med. Katrin Schweneker
at 27.11.2026

From the clinic to the microscope: integrated diagnostics in haematology

At our continuing education event, 'From the Clinic to the Microscope: Integrated Diagnostics in Haematology', taking place on 27 and 28 November 2026, we aim to explore the impact of clinical practice and diagnostics on treatment decisions. You can find all the information you need here.

Read more

Tamara Bäßler
at 16.10.2026

Vom Biomarker zur Therapie

The 8th Oncology Symposium, hosted by the publisher Trillium, will explore the latest developments in precision oncology, including biomarkers, liquid biopsies, and AI-assisted diagnostics and therapy in German.

Read more